 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 14, 2021 GLOBE NEWSWIRE -- TLC Nasdaq: TLC, TWO: 4152, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the first quarter ended March 31, 2021 and provided a business update. 